A Nature Biotechnology study reported that transplanting human embryonic stem cell‑derived spinal cord neural stem cells (H9‑scNSCs) into injured rhesus monkeys restored forelimb and hand function in a substantial fraction of trials. The paper documented functional recovery in 53% of treated experiments and detailed surgical, behavioral and histological endpoints. Investigators emphasized the grafts’ integration, synaptic connectivity and safety signals, marking a significant step toward clinical translation for spinal cord injury. The study addressed dosing, delivery route and immunosuppression variables relevant to first‑in‑human plans. While promising, authors and reviewers noted remaining hurdles: reproducibility, long‑term safety, immune management and manufacturing scale. The data support accelerated development but underscore the need for carefully designed early‑phase human trials and robust regulatory engagement.